BMS-F is a chemical from the aminoalkylindole family invented by Bristol-Myers Squibb around 1999, that acts as a potent and selective agonist for the cannabinoid receptor CB2, with a Ki of 8 nM at CB2 and 500x selectivity over the related CB1 receptor. It has antiinflammatory effects and inhibits release of TNF-α.
See also
- A-796,260
- APP-FUBINACA
- JWH-200
- MDMB-FUBINACA
- MN-25
- Pravadoline
- S-777,469
- WIN 55,212-2
References
